Ironwood Pharmaceuticals, Inc. - Class A (IRWD) Stock Price

IRWDStock

$4.13+212.88%52W

Market Cap$682.44M

P/E28.59x

PEG Ratio—

Div yield—

Beta0.21

IRWD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-2.96%

Price vs S&P 500 (4W)-8.10%

VGM Score69.96

P/E Ratio (Annual)28.59x

P/CF (Annual)5.40x

Book Value / Share (Quarterly)$4.55

P/TBV (Annual)2.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-10.32%

Cash Flow / Share (Quarterly)$0.68

Price vs S&P 500 (YTD)9.73%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)28.26%

EPS (TTM)$0.58

10-Day Avg Trading Volume1.48M

EPS Excl Extra (TTM)$0.58

Revenue Growth (5Y)-5.33%

EPS (Annual)$0.15

ROI (Annual)16.69%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-9.53%

Cash / Share (Quarterly)$1.34

P/E Basic Excl Extra (TTM)6.72x

Revenue Growth QoQ (YoY)158.87%

EPS Growth (5Y)-25.92%

P/E Normalized (Annual)28.59x

ROA (Last FY)6.05%

Revenue Growth TTM (YoY)13.80%

EBITD / Share (TTM)$1.26

ROE (5Y Avg)-206.33%

Operating Margin (TTM)55.37%

Cash Flow / Share (Annual)$0.78

P/B Ratio0.97x

P/B Ratio (Quarterly)2.31x

Net Income / Employee (Annual)$240,200

EV / Revenue (TTM)2.91x

Net Interest Coverage (TTM)3.44x

ROA (TTM)26.02%

EPS Growth QoQ (YoY)889.04%

EV / EBITDA (TTM)5.20x

EPS Incl Extra (Annual)$0.15

Current Ratio (Annual)1.13x

Quick Ratio (Quarterly)1.38x

3-Month Avg Trading Volume2.32M

52-Week Price Return212.88%

EV / Free Cash Flow (Annual)8.27x

P/E Incl Extra (TTM)6.72x

Revenue / Employee (TTM)$3,615,100

Tangible BV / Share (Quarterly)$-2.10

P/S Ratio (Annual)2.32x

Asset Turnover (Annual)0.75x

52-Week High$5.78

Operating Margin (5Y Avg)-7.34%

EPS Excl Extra (Annual)$0.15

CapEx CAGR (5Y)-54.79%

26-Week Price Return8.97%

Quick Ratio (Annual)1.08x

13-Week Price Return14.72%

Total Debt / Equity (Annual)0.61x

Current Ratio (Quarterly)1.41x

Enterprise Value$1.05B

Revenue / Share Growth (5Y)-5.60%

Asset Turnover (TTM)0.92x

Book Value / Share Growth (5Y)44.86%

Revenue / Employee (Annual)$2,961,500

Inventory Turnover (Annual)79.67x

Pretax Margin (Annual)23.65%

Cash / Share (Annual)$1.32

3-Month Return Std Dev65.79%

Gross Margin (5Y Avg)96.84%

Net Income / Employee (TTM)$1,021,800

EBITDA CAGR (5Y)-7.28%

EBITDA Interim CAGR (5Y)9.78%

ROE (Last FY)26.83%

Net Interest Coverage (Annual)6.93x

EPS Basic Excl Extra (Annual)$0.15

P/FCF (TTM)5.39x

Receivables Turnover (TTM)4.97x

EV / Free Cash Flow (TTM)9.37x

Total Debt / Equity (Quarterly)0.56x

EPS Incl Extra (TTM)$0.58

Receivables Turnover (Annual)4.60x

ROI (TTM)17.90%

P/S Ratio (TTM)1.90x

Pretax Margin (5Y Avg)-12.39%

Revenue / Share (Annual)$1.82

Tangible BV / Share (Annual)$4.24

Forward P/E3.09x

Free OCF CAGR (5Y)-5.33%

Price vs S&P 500 (52W)194.32%

P/E Ratio (TTM)6.72x

EPS Growth TTM (YoY)2150.00%

Year-to-Date Return22.55%

5-Day Price Return0.00%

EPS Normalized (Annual)$0.15

ROA (5Y Avg)-28.73%

Net Profit Margin (Annual)8.11%

Month-to-Date Return-2.36%

Cash Flow / Share (TTM)$-5.48

EBITD / Share (Annual)$0.62

EPS Growth (3Y)-46.07%

Operating Margin (Annual)33.26%

LT Debt / Equity (Annual)0.61x

P/CF (TTM)6.12x

ROI (5Y Avg)8.20%

P/E Excl Extra (TTM)6.72x

LT Debt / Equity (Quarterly)0.56x

EPS Basic Excl Extra (TTM)$0.58

P/B Ratio (Annual)2.91x

Inventory Turnover (TTM)16.12x

Pretax Margin (TTM)47.43%

Book Value / Share (Annual)$4.24

Price vs S&P 500 (13W)12.77%

Net Margin Growth (5Y)-21.54%

Beta0.21x

P/FCF (Annual)5.41x

Revenue / Share (TTM)$2.17

ROE (TTM)29.31%

52-Week Low$1.01

vGradeB

gGradeC

mGradeB

vgmGradeB

IRWD Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	$0.28	$0.31	+12.73%(+$0.03)
Q1 2026	May 7, 2026	$0.24	$0.24	+0.00%(+$0.00)
Q4 2025	Feb 25, 2026	$0.01	-$0.01	-200.00%(-$0.02)
Q3 2025	Nov 10, 2025	$0.12	$0.24	+108.70%(+$0.12)
Q2 2025	Aug 7, 2025	$0.04	$0.14	+250.00%(+$0.10)

IRWD Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.90

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
IRWDIronwood Pharmaceuticals, Inc. - Class A	B	C	B	$4.13
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Ironwood Pharmaceuticals, Inc. - Class A

Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. The company markets LINZESS and CONSTELLA (both linaclotide) for the treatment of irritable bowel syndrome with constipation, chronic constipation, and functional constipation across North America, Europe, and Asia-Pacific regions.